Sunshine Biopharma (NASDAQ:SBFMW – Get Free Report) is expected to be issuing its results before the market opens on Tuesday, November 10th. Analysts expect Sunshine Biopharma to announce earnings of ($3.40) per share and revenue of $9.60 million for the quarter.
Sunshine Biopharma Trading Down 4.7%
NASDAQ:SBFMW traded down $0.00 during trading hours on Tuesday, reaching $0.02. 5,001 shares of the company’s stock were exchanged, compared to its average volume of 13,375. Sunshine Biopharma has a 12 month low of $0.02 and a 12 month high of $0.65. The business’s 50-day simple moving average is $0.04 and its two-hundred day simple moving average is $0.08.
Sunshine Biopharma Company Profile
Sunshine Biopharma, Inc is a biotechnology and pharmaceutical company focused on developing therapeutics for cancer and other serious diseases. Its lead drug candidate, Adva-27a, is a small-molecule anticancer compound designed to inhibit topoisomerase II and has been investigated for activity against certain multidrug-resistant cancer cells, including breast and gastric cancer models.
The company has also pursued messenger RNA-based therapeutics and vaccine-related research, including programs intended to address viral diseases.
Featured Stories
- Five stocks we like better than Sunshine Biopharma
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
- Tempus AI Surges on Earnings Beat, But Can the Rally Last?
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
